Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Atz

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Nature Chemistry|November 23, 2023
Enabling late-stage drug diversification by high-throughput experimentation with geometric deep learningDavid F Nippa, Kenneth Atz, Remo Hohler, et al.
Nature Communications|January 17, 2025
Author Correction: Prospective de novo drug design with deep interactome learningKenneth Atz, Leandro Cotos, Clemens Isert, et al.
Nature Communications|April 22, 2024
Prospective de novo drug design with deep interactome learningKenneth Atz, Leandro Cotos, Clemens Isert, et al.
Journal of Medicinal Chemistry|November 22, 2019
Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 ReceptorsAchi Haider, Julian Kretz, Luca Gobbi, et al.
Chembiochem : a European Journal of Chemical Biology|November 28, 2024
Development of a Highly Selective NanoBRET Probe to Assess MAGL Inhibition in Live CellsThais Gazzi, Benjamin Brennecke, Valentas Olikauskas, et al.
Journal of Medicinal Chemistry|August 14, 2020
Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 ReceptorsAchi Haider, Luca Gobbi, Julian Kretz, et al.
Theranostics|December 8, 2025
Translational molecular imaging and drug development in multiple sclerosisDaniel Tay, Hazem Ahmed, Alyaa Dawoud, et al.
Nature Communications|November 25, 2025
Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimizationDavid F Nippa, Kenneth Atz, Yannick Stenzhorn, et al.
Chemical Science|March 20, 2026
Single-position ligand modifications tune CB<sub>2</sub>R activity by targeting the toggle switchRudolf L Z Ganzoni, Miroslav Kosar, Yongqi Han, et al.
Chimia|September 2, 2024
Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System ProjectsJohannes Aebi, Kenneth Atz, Simon M Ametamey, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Nature Chemistry|November 23, 2023
Enabling late-stage drug diversification by high-throughput experimentation with geometric deep learningDavid F Nippa, Kenneth Atz, Remo Hohler, et al.
Nature Communications|January 17, 2025
Author Correction: Prospective de novo drug design with deep interactome learningKenneth Atz, Leandro Cotos, Clemens Isert, et al.
Nature Communications|April 22, 2024
Prospective de novo drug design with deep interactome learningKenneth Atz, Leandro Cotos, Clemens Isert, et al.
Journal of Medicinal Chemistry|November 22, 2019
Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 ReceptorsAchi Haider, Julian Kretz, Luca Gobbi, et al.
Chembiochem : a European Journal of Chemical Biology|November 28, 2024
Development of a Highly Selective NanoBRET Probe to Assess MAGL Inhibition in Live CellsThais Gazzi, Benjamin Brennecke, Valentas Olikauskas, et al.
Journal of Medicinal Chemistry|August 14, 2020
Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 ReceptorsAchi Haider, Luca Gobbi, Julian Kretz, et al.
Theranostics|December 8, 2025
Translational molecular imaging and drug development in multiple sclerosisDaniel Tay, Hazem Ahmed, Alyaa Dawoud, et al.
Nature Communications|November 25, 2025
Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimizationDavid F Nippa, Kenneth Atz, Yannick Stenzhorn, et al.
Chemical Science|March 20, 2026
Single-position ligand modifications tune CB<sub>2</sub>R activity by targeting the toggle switchRudolf L Z Ganzoni, Miroslav Kosar, Yongqi Han, et al.
Chimia|September 2, 2024
Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System ProjectsJohannes Aebi, Kenneth Atz, Simon M Ametamey, et al.
Pageof 4